Retension Pharmaceuticals
| General Information | |
| Business: | (Incorporated in Delaware) We are a clinical stage biotech developing just one drug candidate, RTN-001, a daily pill for uncontrolled and resistant hypertension. We are evaluating RTN-001 in a Phase 2b trial that began in October 2025. We expect initial data in the first half of 2027.
(Note: Retension Pharmaceuticals filed its S-1 for its IPO on Sept. 18, 2026, without disclosing the terms. Estimated proceeds are $60 million.) |
| Industry: | Pharmaceuticals |
| Employees: | |
| Founded: | 2023 |
| Contact Information | |
| Address | Falls Church, Virginia |
| Phone Number | |
| Web Address | |
| View Prospectus: | Retension Pharmaceuticals |
| Financial Information | |
| Market Cap | |
| Revenues | $ mil (last 12 months) |
| Net Income | $ mil (last 12 months) |
| IPO Profile | |
| Symbol | RTSN |
| Exchange | NASDAQ |
| Shares (millions): | 0.0 |
| Price range | $0.00 - $0.00 |
| Est. $ Volume | $60.0 mil |
| Manager / Joint Managers | Leerink Partners/Guggenheim Securities/Oppenheimer & Co. |
| CO-Managers | |
| Expected To Trade: | |
| Status: | TBA |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |